Table 1 Top MeSh and GO terms associated with papers belonging to each of the eight clusters
MeSH and GO terms | Papers labeled with the term |
|---|---|
Cluster 1 | |
Doxorubicin | 58 |
Liposomes | 58 |
Pharmaceutical preparations | 45 |
Animals | 38 |
Neoplasms | 32 |
Cluster 2 | |
Doxorubicin | 57 |
Liposomes | 57 |
Humans | 50 |
Patients | 44 |
Female | 44 |
Neoplasms | 41 |
Adult | 35 |
Middle aged | 35 |
Therapeutics | 30 |
Aged | 29 |
Drug carriers | 29 |
Cluster 3 | |
Liposomes | 50 |
Doxorubicin | 48 |
Cells | 40 |
cell | 40 |
Animals | 38 |
Pharmaceutical preparations | 37 |
Mice | 36 |
Humans | 35 |
Neoplasms | 31 |
Cluster 4 | |
Liposomes | 33 |
Doxorubicin | 30 |
Pharmaceutical preparations | 30 |
Neoplasms | 27 |
Animals | 27 |
Therapeutics | 24 |
Drug Carriers | 22 |
Mice | 22 |
Humans | 19 |
Cluster 5 | |
Doxorubicin | 34 |
Liposomes | 34 |
Pharmaceutical preparations | 28 |
Animals | 25 |
Neoplasms | 25 |
Temperature | 18 |
Cluster 6 | |
Doxorubicin | 16 |
Humans | 16 |
Liposomes | 15 |
Patients | 14 |
Male | 14 |
Middle aged | 12 |
Aged | 12 |
Female | 12 |
Treatment outcome | 11 |
Polyethylene glycols | 9 |
Therapeutics | 9 |
Adult | 9 |
Cluster 7 | |
Doxorubicin | 10 |
Liposomes | 10 |
Patients | 9 |
Humans | 9 |
Female | 8 |
Breast neoplasms | 8 |
Survival | 7 |
Neoplasms | 7 |
Therapeutics | 7 |
Aged | 7 |
Adult | 6 |
Middle aged | 6 |
Safety | 6 |
Cluster 8 | |
Doxorubicin | 9 |
Liposomes | 9 |
Patients | 9 |
Recurrence | 9 |
Survival | 9 |
Adult | 9 |
Aged | 9 |
Female | 9 |
Humans | 9 |
Middle aged | 9 |
Ovarian neoplasms | 9 |
Platinum | 8 |
Polyethylene glycols | 8 |
Disease-free survival | 7 |
Neoplasms | 7 |
Safety | 6 |
Aged, 80 and over | 6 |